A Recurrent Small Cell Lung Carcinoma Harboring an EML4-ALK Fusion Mutation with Sustained Response to Ensartinib: A Case Report.

Curr Oncol · 2025 · PMC11941435 · PMID 40136367

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

As this patient showed a trend toward improvement on imaging after a month-long course of ensartinib, we elected to continue treatment at ensartinib 200 mg daily for this patient.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.